Keyword: Abbott Laboratories
Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.
Official statistics show a 59% year-on-year drop in foreign direct investment over the first nine months of 2017.
Check out the top stories from 2017—from "artificial pancreas" developments to corporate drama and the evolution of med tech.
CMS covers traditional insulin pumps, but not tubeless patch pumps, causing concern around innovation as well as patient access.
The series B gives Bigfoot the financial muscle to move its automated insulin infusion device into a pivotal clinical trial in the U.S. next year.
The court case follows Alere’s decision to sell its BNP assay business and associated supply agreements to Quidel to clear antitrust barriers.
Medtronic’s Intellis platform grabbed a CE mark for peripheral nerve and spinal cord stimulation. With the nod, the device is now cleared to treat chronic, intractable pain of the trunk, posterior trunk and limbs.
Medtronic has posted a look at data on the first 50 patients treated with its transcatheter mitral valve replacement (TMVR) system.
The candidate is designed to induce production of relaxin, a hormone seen as a way to regulate the conditions that exacerbate heart failure.
Here's Monday's medtech news of note.